🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/10/2022 26,54 28,08 26,12 27,11 +3,67% 7,39% 519.500
10/10/2022 26,66 26,79 25,52 26,15 -2,32% 4,74% 436.500
07/10/2022 28,46 28,61 26,43 26,77 -7,75% 7,66% 669.200
06/10/2022 27,53 29,83 27,25 29,02 +4,31% 9,37% 1.150.800
05/10/2022 26,42 28,15 26,40 27,82 +3,42% 6,62% 527.300
04/10/2022 26,60 27,15 26,19 26,90 +2,67% 3,61% 508.800
03/10/2022 26,64 27,24 25,64 26,20 +0,15% 6,01% 533.300
30/09/2022 26,00 27,18 25,77 26,16 +2,47% 5,44% 529.100
29/09/2022 26,33 26,45 25,14 25,53 -4,74% 4,98% 532.500
28/09/2022 26,57 27,11 26,10 26,80 +3,51% 3,80% 626.700
27/09/2022 25,04 26,61 25,01 25,89 +5,59% 6,39% 764.300
26/09/2022 25,29 25,83 24,51 24,52 -2,74% 5,22% 492.900
23/09/2022 25,09 25,42 24,48 25,21 +0,00% 3,75% 585.900
22/09/2022 24,96 25,44 24,30 25,21 -0,16% 4,59% 490.800
21/09/2022 26,40 26,77 25,21 25,25 -4,90% 5,91% 705.400
20/09/2022 25,21 27,29 25,19 26,55 +3,91% 8,31% 540.500
19/09/2022 25,63 25,96 24,98 25,55 -1,43% 3,82% 740.400
16/09/2022 26,28 26,36 24,91 25,92 -3,50% 5,52% 2.196.400
15/09/2022 25,99 27,48 25,73 26,86 +3,35% 6,73% 462.900
14/09/2022 25,29 26,04 24,73 25,99 +3,63% 5,18% 605.000
13/09/2022 24,80 25,38 24,63 25,08 -2,68% 3,04% 1.041.400
12/09/2022 25,42 25,83 24,94 25,77 +1,22% 3,50% 308.200
09/09/2022 25,76 26,35 25,26 25,46 -0,93% 4,21% 381.500
08/09/2022 24,15 26,08 24,15 25,70 +4,86% 7,99% 530.500
07/09/2022 23,13 24,51 23,13 24,51 +5,51% 5,97% 665.400
06/09/2022 25,04 25,04 23,19 23,23 -6,33% 7,39% 621.600
02/09/2022 26,05 26,24 24,47 24,80 -3,58% 6,79% 589.700
01/09/2022 23,72 25,89 23,52 25,72 +6,81% 9,99% 518.800
31/08/2022 24,31 24,78 23,75 24,08 -0,04% 4,24% 458.400
30/08/2022 24,96 25,07 23,78 24,09 -2,35% 5,17% 466.000